Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)
Israel
· Delayed Price · Currency is ILS · Price in ILA 157.00
-2.10 (-1.32%)
Apr 24, 2025, 5:24 PM IDT
Novolog (Pharm-Up 1966) Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,022 | 1,643 | 1,508 | 1,255 | 1,134 | Upgrade
|
| Revenue Growth (YoY) | 23.01% | 8.99% | 20.13% | 10.73% | 12.90% | Upgrade
|
| Cost of Revenue | 1,841 | 1,470 | 1,328 | 1,101 | 1,003 | Upgrade
|
| Gross Profit | 180.78 | 173.76 | 179.7 | 154.67 | 130.97 | Upgrade
|
| Selling, General & Admin | 110.86 | 123.29 | 101.59 | 83.71 | 63.92 | Upgrade
|
| Other Operating Expenses | 7.57 | -3.49 | 0.31 | 1.55 | 0.2 | Upgrade
|
| Operating Expenses | 118.43 | 119.8 | 101.89 | 85.26 | 73.44 | Upgrade
|
| Operating Income | 62.35 | 53.97 | 77.81 | 69.41 | 57.54 | Upgrade
|
| Interest Expense | -17.12 | -12.87 | -12.54 | -8.47 | -7.39 | Upgrade
|
| Interest & Investment Income | - | 12.02 | 5.54 | 2.5 | 0.8 | Upgrade
|
| Earnings From Equity Investments | -0.44 | -30.64 | -4.61 | -1.64 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.07 | 1.36 | -0.97 | -0.98 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.9 | - | - | -1.22 | -1 | Upgrade
|
| EBT Excluding Unusual Items | 57.68 | 22.4 | 67.55 | 59.6 | 48.97 | Upgrade
|
| Impairment of Goodwill | - | -50.67 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.5 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.14 | 0.34 | 0.53 | 3.56 | Upgrade
|
| Pretax Income | 57.68 | -28.91 | 67.89 | 60.13 | 52.52 | Upgrade
|
| Income Tax Expense | 16.69 | 10.47 | 16.98 | 15.31 | 11.96 | Upgrade
|
| Earnings From Continuing Operations | 41 | -39.39 | 50.91 | 44.83 | 40.56 | Upgrade
|
| Minority Interest in Earnings | -1.46 | -2.62 | -3.4 | -2.51 | -0.49 | Upgrade
|
| Net Income | 39.54 | -42 | 47.51 | 42.32 | 40.07 | Upgrade
|
| Net Income to Common | 39.54 | -42 | 47.51 | 42.32 | 40.07 | Upgrade
|
| Net Income Growth | - | - | 12.27% | 5.62% | 295.25% | Upgrade
|
| Shares Outstanding (Basic) | 513 | 510 | 507 | 505 | 464 | Upgrade
|
| Shares Outstanding (Diluted) | 513 | 511 | 516 | 515 | 472 | Upgrade
|
| Shares Change (YoY) | 0.50% | -0.94% | 0.14% | 9.08% | 22.05% | Upgrade
|
| EPS (Basic) | 0.08 | -0.08 | 0.09 | 0.08 | 0.09 | Upgrade
|
| EPS (Diluted) | 0.08 | -0.08 | 0.09 | 0.08 | 0.09 | Upgrade
|
| EPS Growth | - | - | 12.20% | -3.53% | 226.92% | Upgrade
|
| Free Cash Flow | 145.12 | 129.06 | 63.16 | 52.75 | 32.87 | Upgrade
|
| Free Cash Flow Per Share | 0.28 | 0.25 | 0.12 | 0.10 | 0.07 | Upgrade
|
| Dividend Per Share | - | 0.029 | 0.066 | 0.094 | 0.026 | Upgrade
|
| Dividend Growth | - | -55.19% | -29.97% | 262.10% | -39.79% | Upgrade
|
| Gross Margin | 8.94% | 10.57% | 11.92% | 12.32% | 11.55% | Upgrade
|
| Operating Margin | 3.08% | 3.28% | 5.16% | 5.53% | 5.08% | Upgrade
|
| Profit Margin | 1.96% | -2.56% | 3.15% | 3.37% | 3.53% | Upgrade
|
| Free Cash Flow Margin | 7.18% | 7.85% | 4.19% | 4.20% | 2.90% | Upgrade
|
| EBITDA | 141 | 124.54 | 94.26 | 91.66 | 80.13 | Upgrade
|
| EBITDA Margin | 6.98% | 7.58% | 6.25% | 7.30% | 7.07% | Upgrade
|
| D&A For EBITDA | 78.66 | 70.57 | 16.45 | 22.25 | 22.59 | Upgrade
|
| EBIT | 62.35 | 53.97 | 77.81 | 69.41 | 57.54 | Upgrade
|
| EBIT Margin | 3.08% | 3.28% | 5.16% | 5.53% | 5.08% | Upgrade
|
| Effective Tax Rate | 28.93% | - | 25.01% | 25.45% | 22.77% | Upgrade
|
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.